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ABSTRACT
Objective: To investigate the expression of tumour
necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK) and its receptor fibroblast growth factor inducible
14 (Fn14)intheinflamed synovium ofpatientswith arthritis,
as TWEAK blockade has been observed to have a beneficial
effect in an animal model of rheumatoid arthritis (RA).
Methods: Synovial tissue (ST) biopsies were obtained from
6 early, methotrexate-naive patients with RA as well as 13
patients with RA and 16 patients with psoriatic arthritis
(PsA) who were matched for treatment and disease
duration. Serial ST samples were obtained from a separate
cohort of 13 patients with RA before and after infliximab
treatment. TWEAK and Fn14 expression was evaluated by
immunohistochemistry and digital image analysis.
Results: TWEAK and Fn14 were clearly expressed in ST
of patients with RA and PsA. TWEAK expression was
significantly higher in RA (sub)lining samples compared to
PsA (p=0.005 and p=0.014, respectively), but Fn14
expression was comparable. Double immunofluorescence
showed TWEAK and Fn14 expression on fibroblast-like
synoviocytes and macrophages, but not T cells. Of
interest, persistent TWEAK and Fn14 expression was
found after anti-TNF therapy.
Conclusions: TWEAK and Fn14 are abundantly
expressed in the inflamed synovium of patients with RA
and PsA. This raises the possibility that blocking TWEAK/
Fn14 signalling could be of therapeutic benefit in
inflammatory arthritis.
Tumour necrosis factor (TNF)-like weak inducer of
apoptosis (TWEAK) is a TNF ligand superfamily
member that mediates pleiotropic effects on a
variety of cells via its receptor, fibroblast growth
factor inducible 14 (Fn14). The TWEAK/Fn14
pathway appears to have a physiological role in
the regulation of tissue repair after injury, when
Fn14 expression is highly induced.
1 Fn14 can be
expressed by many cell types, including epithelial,
mesenchymal and endothelial cells, and progenitor
cells of the mesenchymal lineage.
23 Activating
Fn14 can have a number of effects, depending on
cell type and context, including proangiogenic
effects and induction of fibroblast-like synovio-
cytes (FLS) to produce proinflammatory cytokines
and chemokines, such as interleukin (IL)6, IL8 and
Regulated on Activation, Normal T Expressed and
Secreted (RANTES).
34TWEAK may also promote
bone and cartilage destruction through inhibition
of chondrogenesis and osteogenesis and promotion
of osteoclastogenesis.
2
These data raise the possibility that TWEAK
may contribute to chronic synovitis, a notion
supported by the observation that TWEAK expres-
sion is dramatically elevated in the murine
collagen-induced arthritis (CIA) model of arthritis.
Blocking TWEAK signalling reduced the severity of
arthritis in this model, and diminished synovial
inflammation, vascularity, and cartilage and bone
destruction.
25However, very little is known about
the role of the TWEAK/Fn14 pathway in human
inflammatory arthritis. To address this issue, we
examined the expression of TWEAK and Fn14 in
synovial tissue (ST) of patients with rheumatoid
arthritis (RA) and psoriatic arthritis (PsA), in
newly diagnosed, previously untreated patients
with RA, and in patients with RA on methotrexate
before and after treatment with infliximab.
PATIENTS AND METHODS
Patients and synovial tissue acquisition
For a comparative analysis of TWEAK and Fn14
expression, ST biopsies were obtained by arthro-
scopy from 13 patients with RA and 16 patients
with PsA with clinically active arthritis. ST
biopsies from a second cohort of 13 patients with
RA on methotrexate (MTX) therapy were obtained
from the same joint before and 4 weeks after the
initiation of infliximab (IFX) therapy (IFX 3 mg/
kg, administered intravenously at baseline and
2 weeks later).
6 Additionally, ST biopsies were
obtained from 6 patients newly diagnosed as
having RA who had not been treated with any
disease-modifying antirheumatic drug (DMARD).
All patients with RA met the 1987 revised criteria
of the American College of Rheumatology for the
diagnosis of RA.
7 All patients with PsA fulfilled the
CASPAR (for ‘‘ClASsification of Psoriatic
ARthritis’’) group criteria,
8 and had active joint
and skin disease at the time of arthroscopy. ST
biopsies were obtained by arthroscopy from an
actively inflamed knee, ankle or wrist joint under
local anaesthesia.
9 Biopsies were obtained from six
or more sites in each joint. ST biopsies were
immediately embedded in TissueTek OCT (Miles
Diagnostics, Elkhart, Indiana, USA), snap frozen in
liquid nitrogen and stored at 280uC, as previously
described in detail.
91 0All patients provided their
written informed consent and patient clinical and
demographic data were obtained before arthro-
scopy. This study was approved by the local
medical ethics committee.
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ST samples were cut with a cryostat (5 mm), fixed with acetone,
and endogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide. Specific monoclonal antibodies were used to
detect TWEAK (clone P3H8) and Fn14 (clone P2D3) (both from
Biogen Idec, Cambridge, Massachusetts, USA). Bound antibody
was detected with a three-step immunoperoxidase method
using a biotinylated tyramine amplification method.
11 Stained
sections were then randomly analysed using digital image
analysis (DIA), as previously described in detail.
12 Expression of
TWEAK and Fn14 is presented as integrated optical density
(IOD)/mm
2, an arbitrary unit representing the amount of
staining per mm
2.
13
Double immunofluorescence
TWEAK and Fn14 expression in distinct synovial cell popula-
tions was assessed by double immunofluorescence in 15
randomly selected patients (8 with PsA and 7 with RA).
Sections were incubated overnight at 4uC with primary
monoclonal antibodies against TWEAK and Fn14, and then
labelled with streptavidin-ALEXA 594 (Invitrogen/Molecular
Probes, Breda, The Netherlands) for 30 min. Next, sections were
blocked with 10% normal mouse serum, incubated for 30 min
with fluorescein isothiocyanate (FITC)-labelled markers for
CD55 (clone BRIC 110, Sanquin, Amsterdam, The
Netherlands), CD3 (clone SK7, Becton Dickinson, San Jose,
California, USA) and CD68 (clone KP1, Dako, Glostrop,
Table 1 Demographic data of the first cohort of patients with psoriatic
arthritis (PsA) and rheumatoid arthritis (RA)
PsA (n=16) RA (n=13)
Female, no (%) 6 (38%) 6 (46%)
Age in years, mean (range) 46.5 (22–64) 52.6 (38–69)
Disease duration in months, mean (range) 120 (39–284) 137 (10–278)
RF and/or anti-CCP positive, no (%) 2 (13%) 13 (100%)
Erosions, no (%) of patients 8 (50%) 11 (88%)
ESR mm/h, median (IQR) 21.5 (7.3–32.3) 28.0 (9.5–47.5)
CRP mg/litre, median (IQR) 10.4 (2.5–23.7) 7.0 (3.5–35.5)
Methotrexate dose (mg), mean (SD) 16.7 (7.2) 20.0 (4.3)
Patients with RA were more often RF and/or anti-CCP positive than patients with PsA.
No other significant differences in the clinical data between patients with RA and PsA
were detectable.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate; IQR, interquartile range (25th–75th percentile); RF, rheumatoid factor.
Figure 1 Representative photographs showing tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) expression (reddish-brown
staining) in rheumatoid arthritis (RA) synovial tissue (ST) (a–c) and psoriatic arthritis (PsA) ST (d–f). Overview of RA ST (a) (original magnification
1006), and close up of the intimal lining layer (b) and the synovial sublining with (peri)vascular staining (c) (magnification 2006); overview of PsA ST
(d), and close up of the intimal lining layer (e) and the synovial sublining with (peri)vascular staining (f).
Concise report
302 Ann Rheum Dis 2010;69:301–304. doi:10.1136/ard.2008.090548Denmark), covered with VectaShield mounting medium
(H-1200, Vector laboratories, Burlingame, California, USA), and
analysed with a wide-field upright microscope (Leica DMRA,
Wetzlar, Germany) coupled to a CCD camera and Image-Pro Plus
software (Media Cybernetics, Dutch Vision Components, Breda,
The Netherlands). Coexpression of CD68, CD55 and CD3 with
TWEAK and Fn14 was determined by the manual counting of
positive cells by two independent blinded observers (Tom Smeets
and Dion Groot, Academic Medical Center/University of
Amsterdam, Amsterdam, The Netherlands).
Statistical analysis
To compare the differences in expression of TWEAK and Fn14
between groups the Mann–Whitney U test for non-parametric
data was used. Correlations were assessed using the Spearman
rank correlation coefficient. Serial biopsies were evaluated using
the Wilcoxon signed rank test. A p value of ,0.05 was
considered statistically significant.
RESULTS
Table 1 shows the patient characteristics of the first patient
cohort (13 patients with RA and 16 with PsA) who were used
for cross sectional comparison. All these patients were treated
with methotrexate; there was a trend towards slightly higher
dosages in RA, but this difference was not statistically
significant. In both groups one patient was also treated with
prednisolone 10 mg daily. Most patients had longstanding
disease and displayed comparable erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) levels, indicating
similar degrees of inflammatory activity.
In RA and PsA ST, strong expression of TWEAK was observed
in the intimal lining layer and the synovial sublining, including
perivascular regions in a subset of blood vessels (fig 1). Expression
of TWEAK was higher in RA than in PsA in the intimal lining
layer (median and interquartile range (IQR)), respectively 45 305
(21 410–63 456) versus 14 381 (934–20 002) IOD/mm
2
(p=0.005) and the synovial sublining 44 941 (30 687–106 183)
versus 8022 (2484–70 439) IOD/mm
2 (p=0.014). Fn14 was
expressed in the intimal lining layer and the perivascular regions
of the synovial sublining (fig 2). Fn14 expression was not
significantly different between RA and PsA. Immunofluorescent
double staining revealed frequent TWEAK (65%) and Fn14 (46%)
expression in CD55+ RA FLS. CD68+ macrophages also
frequently expressed TWEAK (46%) and Fn14 (20%). In contrast,
CD3+ T cells hardly expressed any TWEAK or Fn14.
Figure 2 Representative photographs showing tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) receptor fibroblast growth
factor inducible 14 (Fn14) expression (reddish-brown staining) in rheumatoid arthritis (RA) synovial tissue (ST) (a–c) and psoriatic arthritis (PsA)
synovial tissue (d–f). Overview of RA ST (a) (original magnification 1006), and close up of the intimal lining layer (b) and the synovial sublining (c)
(magnification 2006); overview of PsA ST (d), and close up of the intimal lining layer (e) and the synovial sublining (f).
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arthroscopy before and 4 weeks after initiation of infliximab
infusions. Patients had longstanding disease (mean disease
duration 127 months, range 10–311), all were treated with
MTX (mean dose 15 mg/week, range 5–30) and 10/13 with
prednisolone (mean dose 9 mg/day, range 2.5–15). The 28-joint
Disease Activity Score (DAS28) was significantly reduced
following 4 weeks of infliximab therapy: DAS28 (median and
IQR) at baseline, 6.25 (5.57–7.04); after 4 weeks, 4.48 (3.82–
5.98) (p,0.01). However, there was persistent TWEAK expres-
sion after TNF blockade without any significant changes in ST
TWEAK or Fn14 expression following infliximab therapy.
To rule out the possibility that the expression of TWEAK and
Fn14 had been influenced considerably by disease duration or
DMARD treatment in the above mentioned cohorts, ST
samples from a third cohort of 6 recently diagnosed patients
with RA who had not yet been treated with DMARDs was
studied and compared to the 13 patients with RA from the
second cohort. The expression of TWEAK and Fn14 was
comparable between this group with early disease and the
abovementioned group with longstanding disease before start of
infliximab therapy, indicating that TWEAK and its receptor are
expressed in early RA.
DISCUSSION
TWEAK and Fn14 are both abundantly expressed in the
inflamed synovium of patients with (early) RA and PsA, where
they may promote synovial inflammation and joint destruction.
Of importance, there is persistent expression of TWEAK and its
receptor after TNF blockade. TWEAK expression in the intimal
lining layer and synovial sublining is significantly higher in RA
compared to PsA, while Fn14 expression is similar. TWEAK and
Fn14 are mainly expressed by FLS and, to a lesser extent,
macrophages, suggesting that both effector cells may participate
in TWEAK responses in patients with arthritis.
The TWEAK/Fn14 pathway appears to have a physiological
role in the regulation of tissue repair after injury. TWEAK may
initially be produced by tissue cells, and by invading inflamma-
tory cells such as monocytes. The TWEAK-Fn14 pathway might
then drive chemokine and cytokine production, resulting in
additional infiltration of proinflammatory cells, and facilitate
angiogenesis and the proliferation of progenitor cells needed for
tissue repair. Chronic expression of TWEAK and Fn14 in
inflammatory arthritis may subvert processes beneficial in acute
tissue repair to pathogenic contributions. The expression of
TWEAK and Fn14 in chronic synovitis could contribute to
persistent inflammation and progressive destruction of the joint
tissue by the production of chemokines, cytokines and MMPs,
and promotion of cell proliferation and angiogenesis. Because
the TWEAK/Fn14 pathway does not appear to be involved in
the regulation of adaptive immunity, it has been suggested that
blocking TWEAK/Fn14 activation would potentially have a
favourable safety profile. Further studies are needed to identify
the contributions of TWEAK/Fn14 to inflammatory arthritis,
and the therapeutic potential of targeting this pathway.
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